Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
Department of Pharmacognosy, College of Pharmacy, King Khalid University (KKU), Guraiger, Abha, Saudi Arabia.
J Alzheimers Dis. 2023;96(2):827-844. doi: 10.3233/JAD-230828.
Tyrosine-protein kinase Fyn (Fyn) is a critical signaling molecule involved in various cellular processes, including neuronal development, synaptic plasticity, and disease pathogenesis. Dysregulation of Fyn kinase has been implicated in various complex diseases, including neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, as well as different cancer types. Therefore, identifying small molecule inhibitors that can inhibit Fyn activity holds substantial significance in drug discovery.
The aim of this study was to identify potential small-molecule inhibitors among bioactive phytoconstituents against tyrosine-protein kinase Fyn.
Through a comprehensive approach involving molecular docking, drug likeliness filters, and molecular dynamics (MD) simulations, we performed a virtual screening of a natural compounds library. This methodology aimed to pinpoint compounds potentially interacting with Fyn kinase and inhibiting its activity.
This study finds two potential natural compounds: Dehydromillettone and Tanshinone B. These compoundsdemonstrated substantial affinity and specific interactions towards the Fyn binding pocket. Their conformations exhibitedcompatibility and stability, indicating the formation of robust protein-ligand complexes. A significant array of non-covalentinteractions supported the structural integrity of these complexes.
Dehydromillettone and Tanshinone B emerge as promising candidates, poised for further optimization as Fynkinase inhibitors with therapeutic applications. In a broader context, this study demonstrates the potential of computationaldrug discovery, underscoring its utility in identifying compounds with clinical significance. The identified inhibitors holdpromise in addressing a spectrum of cancer and neurodegenerative disorders. However, their efficacy and safety necessitatevalidation through subsequent experimental studies.
酪氨酸蛋白激酶 Fyn(Fyn)是一种参与多种细胞过程的关键信号分子,包括神经元发育、突触可塑性和疾病发病机制。Fyn 激酶的失调与多种复杂疾病有关,包括神经退行性疾病,如阿尔茨海默病和帕金森病,以及不同类型的癌症。因此,鉴定能够抑制 Fyn 活性的小分子抑制剂在药物发现中具有重要意义。
本研究旨在从生物活性植物成分中鉴定针对酪氨酸蛋白激酶 Fyn 的潜在小分子抑制剂。
通过涉及分子对接、药物相似性筛选和分子动力学(MD)模拟的综合方法,我们对天然化合物库进行了虚拟筛选。这种方法旨在确定可能与 Fyn 激酶相互作用并抑制其活性的化合物。
本研究发现了两种潜在的天然化合物:脱水千里光酮和丹参酮 B。这些化合物与 Fyn 结合口袋表现出显著的亲和力和特异性相互作用。它们的构象表现出兼容性和稳定性,表明形成了稳定的蛋白质-配体复合物。大量的非共价相互作用支持这些复合物的结构完整性。
脱水千里光酮和丹参酮 B 是有前途的候选物,有望进一步优化为具有治疗应用的 Fyn 激酶抑制剂。从更广泛的角度来看,本研究展示了计算药物发现的潜力,强调了其在鉴定具有临床意义的化合物方面的效用。鉴定出的抑制剂有望解决一系列癌症和神经退行性疾病。然而,它们的疗效和安全性需要通过后续的实验研究来验证。